P-PSMA-101 Clinical Program Delayed; Poseida’s Global Collaboration with Roche; Poseida Q2 2022 Earnings Summary
Here is a brief preview of this blast: On Thursday, August 11, 2022, Poseida released their Q2 2022 results (press release) highlighting anticipated clinical updates for H2 2022 and the recent partnership with Roche. Below, Celltelligence provides insights on a potential delay for Poseida’s P-PSMA-101 (autologous PSMA CAR-T) program, while discussing Poseida's partnering strategy.